An educational review of cartilage repair: precepts & practice – myths & misconceptions – progress & prospects  by Hunziker, E.B. et al.
Osteoarthritis and Cartilage 23 (2015) 334e350ReviewAn educational review of cartilage repair: precepts & practice emyths
& misconceptions e progress & prospects
E.B. Hunziker*, K. Lippuner a, M.J.B. Keel b, N. Shintani c
Departments of Osteoporosis, Orthopaedic Surgery and Clinical Research, Inselspital, University of Bern, Bern, Switzerlanda r t i c l e i n f o
Article history:
Received 10 July 2014
Accepted 12 December 2014
Keywords:
Articular
Cartilage
Repair
Tissue engineering
Osteoarthritis
Review* Address correspondence and reprint requests
Regenerative Medicine for Skeletal Tissues, Departm
paedic Surgery and Clinical Research, Inselspital, Univ
35, P.O. Box 54, 3010 Bern, Switzerland. Tel: 41-31
49-55.
E-mail addresses: ernst.hunziker@dkf.unibe.ch (E
insel.ch (K. Lippuner), marius.keel@insel.ch (M.J.B.
unibe.ch (N. Shintani).
a Tel: 41-31-632-31-28; Fax: 41-31-632-95-96.
b Tel: 41-31-632-22-13; Fax: 41-31-632-18-80.
c Tel: 41-31-632-09-37; Fax: 41-31-632-49-99.
http://dx.doi.org/10.1016/j.joca.2014.12.011
1063-4584/© 2014 Published by Elsevier Ltd on behas u m m a r y
Objective: The repair of cartilaginous lesions within synovial joints is still an unresolved and weighty
clinical problem. Although research activity in this area has been indefatigably sustained, no signiﬁcant
progress has been made during the past decade. The aim of this educational review is to heighten the
awareness amongst students and scientists of the basic issues that must be tackled and resolved before
we can hope to escape from the whirlpool of stagnation into which we have fallen: cartilage repair
redivivus!
Design: Articular-cartilage lesions may be induced traumatically (e.g., by sports injuries and occupational
accidents) or pathologically during the course of a degenerative disease (e.g., osteoarthritis). This review
addresses the biological basis of cartilage repair and surveys current trends in treatment strategies,
focussing on those that are most widely adopted by orthopaedic surgeons [viz., abrasive chondroplasty,
microfracturing/microdrilling, osteochondral grafting and autologous-chondrocyte implantation (ACI)].
Also described are current research activities in the ﬁeld of cartilage-tissue engineering, which, as a
therapeutic principle, holds more promise for success than any other experimental approach.
Results and Conclusions: Tissue engineering aims to reconstitute a tissue both structurally and func-
tionally. This process can be conducted entirely in vitro, initially in vitro and then in vivo (in situ), or
entirely in vivo. Three key constituents usually form the building blocks of such an approach: a matrix
scaffold, cells, and signalling molecules. Of the proposed approaches, none have yet advanced beyond the
phase of experimental development to the level of clinical induction. The hurdles that need to be sur-
mounted for ultimate success are discussed.
© 2014 Published by Elsevier Ltd on behalf of Osteoarthritis Research Society International.Introduction
The bony ends of mammalian synovial joints are lined with a
layer of articular cartilage (Fig. 1), which permits congruency be-
tween the two opposing skeletal elements, facilitates the transfer of
forces between these and their practically frictionless movement,
and acts as an absorber of weight during sustained static loading1.to: E.B. Hunziker, Center of
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lf of Osteoarthritis Research SocietArticular cartilage is a highly specialized tissue. Lesions therein
seldom heal, or heal only partially under certain biological condi-
tions. They are frequently associated with symptoms such as joint
pain, joint-locking phenomena and reduced or disturbed joint
function. Moreover, the progression of such lesions is generally
believed to forebode the onset of osteoarthritis (OA)2e4.
In Western countries, OA is one of the most common diseases
suffered by elderly persons. It is a disabling joint disorder of
multifactorial aetiology, and, consequently, of usually unknown
origin in individual cases (primary OA). However, it can be
precipitated also by physical injury [e.g., by sports or occupational
accidents (secondary OA)]. The incidence of OA is positively
correlated not only with age but also with obesity, and due to the
upward trends in both life-expectancy and youth overweight, a
steady increase in the prevalence of the disease is expected5e7.
Although joint pain is a common concomitant of OA, this symptom
is not correlated with the size of the articular-cartilage lesion, and
the mechanism underlying its generation is largely unknown8e10.y International.
Fig. 1. Light micrograph of vertically-sectioned articular cartilage, derived from the
femoral condyle of a 17-month-old bovine cow, illustrating its subdivision into su-
perﬁcial (S), transitional (T), upper-radial (UR), lower-radial (LR) and calciﬁed-cartilage
(C) zones; the latter abuts on the subchondral-bone plate (B). 1 mm-thick section,
stained with Toluidine Blue. Bar: 200 mm.
Fig. 2. Schematic drawing of a normal synovial joint.
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and the shoulder, are most frequently affected by OA. During the
early stages of the disease, a localized pattern of lesioning of the
articular-cartilage layer is a characteristic occurrence11. However,
even in unlesioned areas of the affected joint, the metabolism of
the chondrocytes is disturbed12,13. Once initiated, the lesioning
process is progressive, and no prophylactic (medicational) or
interventional measures are at hand to arrest it14e17. Likewise, no
biologically-based treatment strategies are available to induce an
efﬁcacious healing of the structural defects. This review brieﬂy
surveys the biological basis of cartilage repair, as well as current
trends in the treatment of articular-cartilage defects, and points out
the misconceptional elements in these approaches. Particular
emphasis is placed on research activities in the ﬁeld of cartilage-
tissue engineering. The major scientiﬁc and practical hurdles that
need to be overcome for successful articular-cartilage repair are
discussed; so, too, are the shortcomings of repair-evaluation pro-
tocols. Suggestions for improvements in the analytical approach
are made.Lesioning of the articular-cartilage layer
As aforementioned, structural lesioning of an articular-cartilage
layer can be induced either traumatically or during the course of a
disease-based process. Once the process of lesioning has begun, it
cannot be arrested, but progresses inexorably with time, the reason
for which is unknown14e17. Superﬁcial cartilaginous lesions, viz.,
structural defects that are conﬁned to the articular-cartilage layer
itself and do not penetrate the subchondral-bone plate, represent
one of the ﬁrst overt signs of OA (namely, ﬁbrillation of the carti-
laginous layer and loss of proteoglycans therefrom)18e20. Such
lesions do not heal spontaneously21,22. With the lapse of time, they
broaden and lengthen, such that what is initially a discrete condi-
tion progresses insidiously towards a crippling disease.
The reasons why lesions conﬁned to the layer of adult articular
cartilage do not heal lie mainly in the nature of this tissue's struc-
ture and physiology: it is avascular, aneural and harbours but a
sparse population of cells (chondrocytes)23,24, which endure and
remain in their allotted positions throughout the life of the host
(as is the case for neurons of the central nervous system and for
cardiomyocytes). Under metabolically pathological conditions, and
in the vicinity of traumatically-induced lesions, the chondrocytes
respond but sluggishly to internal and external stimuli; they
manifest only a limited proliferative capacity and a reduced
potential for the de-novo synthesis of an extracellular matrix25e27.
Spontaneous repair
From the point of view of its working status, a synovial joint
(Fig. 2) can be considered as an organ. The articular-cartilage layer
represents but one component of a functional unit, having struc-
tural and physiological relationships with the synovial ﬂuid, the
synovial membrane, the subchondral-bone plate and the sub-
chondral-bone marrow, as well as with the trabecular bone and its
vascular system. It is from these associated, highly-vascularized
tissue-compartments that we might expect supportive activities
for articular-cartilage repair21 e as well as destructive inﬂuences28.
It was appreciated already at the beginning of the 20th century that
if articular-cartilage lesions penetrate the layer of subchondral
bone and the bone-marrow spacese and as a consequence become
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ﬁbrin (which acts as the supportive scaffold of a blood clot) e a
limited healing response may ensue26,29. But the repair tissue that
is laid down by the blood-borne and bone-marrow-derived cells of
diverse nature does not endure for more than a few months17,30,31,
and even if it persists for a longer period of time, it is deﬁcient in
functional competence32e35. Despite this poor outlook, many of the
surgical treatment strategies that are in clinical use today
endeavour to foster this spontaneous repair reaction. Interventions
of this kind are often categorized as “bone-marrow-stimulation”
approaches (for review, see27,36e38).
Current surgical strategies
Treatment strategies that exploit the spontaneous repair response
by a “stimulation of the bone marrow”
These surgical approaches include abrasion chondroplasty22,29,
Pridie drilling39 and microfracturing40 (recently reﬁned to micro-
drilling41,42). The aim of these techniques is to expose the lesioned
cartilaginous tissue to the bone-marrow spaces, which, together
with other vicinal compartments (such as the vascular and peri-
vascular spaces, the bony tissue itself, adipose tissue and the
synovium), are thereby stimulated. In essence, these interventions
lead to a spontaneous repair response, which is based upon
surgically-induced bleeding from the subchondral-bone spaces and
subsequent blood-clot formation. The induction of such a sponta-
neous repair response is well known from animal experiments.
However, the ensuing healing response is highly variable and non-
reproducible, and the tissue that is formed is of a ﬁbrous43, unen-
during nature26,30. These techniques were introduced several de-
cades ago44, at which time no alternative or more efﬁcacious
strategies were available, and in the intervening years a consider-
able body of clinical experience has been gained with them.
Various retrospective clinical investigations appertaining to
abrasion chondroplasty have been conducted45e48. The success
rates are quite variable49 and depend upon many factors, such as
the patient's age and physical-activity level, the severity of the
arthritic condition, and the follow-up period. One relevant clinical
trial has been conducted: patients suffering from OA and painful
knee conditions were subjected either to concomitant abrasion
chondroplasty and osteotomy (for realignment and pain relief) or to
osteotomy alone. Individuals who underwent the combined
approach manifested signiﬁcantly higher levels of a “hyaline-like”Fig. 3. Schematic representation of the microfracturing technique. The ﬂoor of a chondral
calibre drill. By this action, the marrow space of the subchondral bone is opened. Blood perc
forms a haematoma.type of cartilaginous repair tissue and lower incidences of tissue
degeneration 12 months after surgery than did those who under-
went osteotomy alone. However, no difference in the clinical
outcome was observed after 2 (and up to 9) years45e49.
The idea of drilling holes through damaged areas of the
articular-cartilage layer into the subchondral bone-marrow spaces
was conceived by Pridie in 195939,50,51. As aforementioned, the
rationale behind this concept is to stimulate a spontaneous repair
reaction. But, perforce, the tissue that is formed is variable in
composition, structure and durability. The intervention is now
performed chieﬂy in young patients with osteoarthritic conditions,
such as osteochondritis dissecans50. The aim is to bring symp-
tomatic relief and to improve joint functionality52,53 by promoting a
resurfacing of the articular layer with a ﬁbrocartilaginous type of
repair tissue. Clinical reports suggest that patients suffering from
generalized arthroses derive the greatest beneﬁts from Pridie
drilling54. However, this procedure appears to confer short-term
beneﬁts only, and only in patients of younger age; in the long-run
(several years after surgery), these beneﬁcial effects are lost55.
The microfracturing technique e a modiﬁcation of the Pridie
approach e was elaborated by Steadman et al.40. After the removal
of the calciﬁed-cartilage layer, multiple holes, 1- to 2-mm in
diameter and 3 to 5 mm apart, are created [with either a pointed
metallic (ice-pick-like) instrument40 or a narrow-calibre drill41,42]
in the bone plate and the bony trabeculae. This process is associated
with bleeding and blood-clot formation (Fig. 3). The technique has
been recently modiﬁed. The improved “microdrilling” version is
better controllable, more reproducible and less traumatic41,42,56.
The microfracturing technique has thus developed into a “micro-
Pridie” drilling approach and relies on the same biological princi-
ples. The advantage of the latter technique was originally believed
to lie in the avoidance of the thermal necrosis that was thought
possible with abrasion and drilling. However, this concern has not
been conﬁrmed either experimentally or clinically. Microdrilling is
now performed more widely than any other bone-marrow-
stimulation technique. Albeit so, no prospective clinical trials
have been undertaken that would either conﬁrm or refute the
claimed advantages of this over other bone-marrow-stimulation
techniques. Microdrilling and microfracturing have been advo-
cated chieﬂy for young patients, in whom good results (improved
joint functionality and relief from pain in 60 to 80% of cases) have
been reported56e59, probably owing to the larger numbers and the
higher activity-levels of the participating precursor-cell pools in
these individuals, thereby leading to a more exuberant repairdefect is perforated in several places using either a pointed instrument or a narrow-
olates into the defect e bearing with it local bone-marrow-derived MSCs e and therein
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microdrilling and microfracturing are most effective in patients
below 40 years of age60, it is questionable whether these tech-
niques would be appropriate for OA-patients, who are usually older,
whose spontaneous tissue-repair potential is impoverished, and in
whom the number and the availability of bone-marrow-derived
stem cells is reduced61e63.
With a view to improving the clinical outcome of microdrilling
and its reproducibility, this intervention has been combined with
the introduction of a thin-layered, blood-absorbing matrix (see
Matrix scaffolds) of either collagen types I and III64,65 or chitosan
glycerol phosphate41,66. However, available data afford little evi-
dence of any beneﬁcial effect of this combined approach. The
disappointing results may reﬂect the relatively high bio-
incompatibility of the implanted matrical material, which triggers
an inﬂammatory response. Indeed, when this combined approach
is adopted, the defect site is confronted not only with the extrinsic
matrix but also with the intrinsic one, namely, ﬁbrin, which ﬁlls
the area after the induction of bleeding, andwhich likewise triggers
an inﬂammatory response. Hence, inﬂammatory reactivity is
augmented by the introduction of an extrinsic matrix. One possible
way to improve the repair result that is achieved in the presence of
an extrinsic matrix is to enhance its biocompatibility and to mini-
mize its pro-inﬂammatory properties. Recent clinical studies that
have been conducted using a collagenous membrane with such
attributes have yielded fairly favourable results67e71. This type of
collagenous matrix is introduced into the defect void after a stim-
ulation of the bone marrow by microdrilling. For this combined
approach, clinicians have coined the term autologous matrix-
induced chondrogenesis (AMIC), which is a misleading misnomer,
since the carrier material is not in itself chondrogenic. The advan-
tages of the AMIC-approach are that it involves no cell-
transplantation, that it can be performed during a single surgical
intervention, and that it is cost-effective. Prospective randomized
clinical trials of a comparative nature are currently underway to
assess the practical usefulness of the AMIC-approach relative to
that of ACI and/or matrix-associated ACI (MACI).
A surer means of achieving an additional improvement in the
clinical outcome of microdrilling-based therapies would be to
introduce an on-the-site-prepared local population of autologous
stem cells (either isolated or in the form of tissue-fragments),
derived, for example, from the synovial membrane or the bone
marrow. An approach that draws on the on-site preparation of
autologous material would involve fewer regulatory hurdles and
circumvent prior laboratory processing, and would, therefore, be
cost-effective. The reproducibility of the repair results could
probably be improved by the introduction of a vehicle-borne
growth-factor cocktail to induce the desired chondrogenic differ-
entiation of the stem cells, which could be conceived as a
commercially-available, off-the-shelf product72e74, and which
would have to be applied together with a functional or structural
barrier75,76 to prevent the up-growth of underlying bone into the
cartilaginous compartment. A concept that is based on the use of
fragments of synovial membrane would be the one most likely to
meet with success, since stem cells of synovial origin have a higher
chondrogenic potential than those derived from either the bone
marrow, the periosteum, adipose tissue or muscle, at least in vitro77.
Moreover, it would even be advantageous to introduce the cells in
the form of tissue-fragments rather than as isolates, since, when
supported by their physiological scaffold, their responsiveness to
the applied chondrogenic differentiation factor(s) would be better
assured78. New treatment strategies should be preferably
conceived from the onset as single surgical interventions or
arthroscopic approaches ewith a view to clinical practicability and
to reduce the risk of infection or other complications, as well as tolessen the burden on health-care systems, which would, in turn,
render them more affordable to the average citizen in Western
societies79.
Transplantation strategies
Osteochondral autografting (mosaicplasty)
The idea of implanting chondral or osteochondral tissue itself
within articular-cartilage defects dates back to the beginning of the
last century80e82. And this concept still forms the basis of clinical
strategies involving both autografts83e86 and allografts87e89. Of the
autologous osteochondral treatment strategies currently in use,
mosaicplasty (Fig. 4) is the one with the longest history. This
technique is used for large, full-thickness lesions, and involves the
introduction of several or multiple pieces (plugs) of autologous
graft-material into the defect void. The advantage of this treatment
strategy is that it can be performed during a single intervention.
Upon exposure and surveillance of the diseased joint, the ortho-
paedic surgeon is able to promptly decide from which regions
autologous donor material should be removed and can then pro-
ceed immediately with the autotransplantation (Fig. 4). Mosaic-
plasty has for some years been the favoured technique of
orthopaedic surgeons in Japan and Europe, but is of only limited
popularity in North America. Indeed, for various reasons (see
below), the approach is now losing credibility among surgeons in
all geographic regions.
One of the most serious drawbacks of the technique relates to
the destiny of the areas from which the autologous osteochondral
plugs are removed. In taking such tissue, the surgeon is artiﬁcially
creating additional lesions within an already diseased joint (Fig. 4),
and in so doing establishes additional sites of joint degeneration,
thereby exacerbating rather than assuaging the local pathological
process. Given the not inconsiderable size of the osteochondral
plugs that are excised by the surgeon, the donor sites probably fail
to heal. For this reason, some surgeons apply a matrical material to
the surgically-created lesions (donor sites), with a view to pro-
moting a spontaneous repair response90. Similarly, we have but a
poor conception of what occurs at the acceptor sites after the
transplantation of autologous tissue-plugs. The drilling procedures
that are used to remove the osteochondral tissue expose chon-
drocytes within the transplanted plug e as well as those bordering
the cavity created at the donor site e to extremely high tempera-
tures and drying conditions, which are liable to impair their vitality.
The osteochondral plugs, once removed, are then press-ﬁtted by
hammering into the subchondral-bone bed. This hammering pro-
cess probably induces an injurious compression of the transplanted
cartilage91, which could precipitate the immediate death of the
chondrocytic population91. Moreover, if the tissue is transferred
from a low to a high-weight-bearing region of the joint, it will be
subjected to unphysiological conditions of mechanical loading for
which it was not conceived, thereby accelerating its degeneration.
The insertion of several serried plugs within the defect void,
without taking measures to promote knitting between them, might
also give rise to complications: the absence of structural bonding
around the entire circumference of each plug will certainly pose
nutritional as well as functional problems from the outset, and
these will tend to prompt tissue degeneration (see Ref. 27). Only a
few attempts have so far been made to clarify these issues. Hence,
although mosaicplasty is still used, there exists no sound scientiﬁc
basis for the contention that patients subjected to this treatment
strategy beneﬁt in the long run92e98.
Osteochondral allografting
For many decades now, allogeneic osteochondral grafts have
been used for the ﬁlling of articular-cartilage defects. The approach
Fig. 4. Schematic representation of the principle of mosaicplasty. Cylindrical plugs of osteochondral tissue are drilled from a non-weight-bearing area of the knee joint (using a
special surgical instrument) and then press-ﬁtted, side-by-side, within the damaged zone. The number of plugs that are removed will depend upon the surface diameter of the
acceptor site. The denuded donor sites are either ﬁlled with osteochondral tissue that is removed from the damaged acceptor site during its surgical preparation for the plugs, or left
empty. When viewed from above, the ﬁtted plugs form a mosaic of circular proﬁles that are interspersed with empty spaces; hence the name “mosaicplasty”.
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sents a means of substituting failed or lost tissue with healthy
articular cartilage, which is usually derived from cadavers80.
The biological rationale for this approach is based on the
knowledge that large osteochondral defects do not heal sponta-
neously and that it is extremely difﬁcult to elaborate a suitable
stimulatory system to promote effective repair in a compartment-
speciﬁc manner within the cartilaginous and the osseous carrels.
It has thus been deemed simpler to replace the lost tissue with
cadaverous osteochondral allografts99e101. Immunological prob-
lems are inevitably to be counted amongst the drawbacks of this
technique102,103. Nevertheless, patients with large osteochondral
defects, such as those generated by tumour resection, osteonec-
rosis, extensive trauma, widespread OA or osteochondritis dis-
secans, beneﬁt greatly from this treatment strategy104,105.
Clinical experience with this therapeutic option has been sur-
prisingly good, immunological reactions being apparently less
extensive in humans than in experimental animals103,106,107. Hu-
man osteochondral allografts also survive for longer periods (some
years), even after freezing or lyophilization87,88,102,108. Clinical
success rates have been reported to range from 65% to 85%, even
after monitoring periods of up to 10 years100,109e111. The major
drawbacks that are associated with the implementation of this
methodology in clinical practice include the scarcity of fresh donor
material and the storage of frozen tissue112. The small but ever-
present risk of disease transmission must also be borne in mind111.
Autologous-chondrocyte implantation (ACI)
When the ACI-technique (Fig. 5) was introduced on the clinical
scene by Brittberg et al. in 1994113, it took the orthopaedic world by
storm, generating much hope and enthusiasm. The concept was infact the brainchild of Grande et al., who tested it in a preclinical
study with rabbits in 1989114. According to the ACI-technique, a
biopsy of healthy articular cartilage is ﬁrst arthroscopically har-
vested from a low- or a non-load-bearing location of the diseased
joint. The cartilaginous tissue is then enzymatically digested to
release the chondrocytes, which are subsequently expanded in
culture, thereby generating more than 10million cells from the few
hundred thousand that are contained within the biopsy. A sus-
pension of the expanded autologous chondrocytes is introduced
directly into the defect, beneath a surgically-sutured periosteal
ﬂap, which is usually removed from the medial tibia. Systems
involving the application of freely-suspended cells are technically
more complex than those in which matrix-embedded cells are
grafted, since the careful placement and suturing of periosteal
ﬂaps (or other types of material with a comparable function) are
required to ensure their retention and optimal integrationwith the
surrounding articular cartilage. Furthermore, the postoperative
delamination of such ﬂaps e which can and does occur, even after
suturing115 e must be prevented by a temporary immobilization
(partial or complete) of the joint. More recently, a matrix-
associated variant of the ACI-approach (the so-called MACI-tech-
nique) was introduced116. According to this MACI-technique, the
autologous chondrocytes are embedded within a matrix (e.g.,
collagen or hyaluronan) rather than suspended in a ﬂuid, thereby
obviating the need for a periosteal ﬂap. However, the use of a
matrix introduces a new set of problems, such as the issues of
bioincompatibility, inﬂammation and degradation (see Trans-
plantation strategies, and Refs. 27,117). The ideal carrier118 has not
yet been developed. Albeit so, this is still a goal towards which
researchers aspire, and efforts in this direction have not been
thwarted by either the slowness of the progress or the set-backs of
failure.
Fig. 5. Schematic representation of the ACI-technique. A fragment of articular cartilage is removed from the periphery of the joint that bears the lesion. This fragment of tissue is
digested to release the chondrocytes, which are expanded in vitro for 11 to 21 days. A periosteal ﬂap is then removed from the medial tibia and sutured over the lesion. A suspension
of the expanded chondrocytes is injected beneath the ﬂap into the lesion.
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surgical intervention is required on two separate occasions, which
is a costly process necessitating long-term patient planning. The
creation of additional lesions within the joint during the harvesting
of healthy cartilage is also a drawback. Although only a small biopsy
is taken from a non-weight-bearing area of the joint, some in-
vestigators claim that this may heighten the risk for the develop-
ment of OA119,120. It has also been suggested that the chondrocytes
could be removed from osteoarthritic rather than from normal
articular cartilage, or even from other tissue sources121,122.
Although the ACI-technique is still highly popular, its superiority
to simpler interventions, such as microfracturing or microdrilling,
has not been established. Knutsen et al.123 have published the re-
sults of a prospective randomized clinical trial in which patients
with circumscribed cartilaginous lesions in the femoral condyle
were treated either conventionally, namely, by microfracturing, or
according to the ACI-technique. The ﬁndings of this 5-year trial
revealed the latter strategy to confer no advantage over the con-
ventional one. Although the repair tissue that was evident 1 year
after treatment according to the ACI-technique was reported to be
structurally superior to that laid down after microfracturing, the
clinical outcome was the same124. An ongoing long-term follow-up
analysis of the same cohort of patients has conﬁrmed the earlier
(5-year) ﬁndings: 15 years after treatment by microfracturing or
according to the ACI-technique, the clinical results were the same in
each group, which argues in favour of the less traumatic, less risky
and less costly microfracturing approach (Gunnar Knutsen: per-
sonal communication). A possible explanation for these short- and
long-term ﬁndings is, that from a biological and biomechanistic
point of view, the treatments are basically the same. When the ACI-
technique is performed, the ﬂoor and the walls of the defect are
usually “neatened” by shaving, which induces local bleeding and a
spontaneous repair response from the bone-marrow spaces.Almost unbelievably, this possibility has not been excluded in the
published studies by the establishment of the appropriate controls
[viz., an “empty” defect (negative control): no injection of chon-
drocytes beneath a periosteal ﬂap114,116; and a defect ﬁlled with
another cell type (positive control), e.g., ﬁbroblasts].
Neither microfracturing/microdrilling nor ACI is clinically
effective in patients over 50 years of age, probably because the
bone-marrow-derived (mesenchymal) stem cells (microfracturing
technique) and the transplanted autologous chondrocytes (ACI-
technique) suffer age-related losses in their potential to proliferate
and differentiate125. Hence, especially for elderly persons, who are
particularly prone to osteoarthritic lesioning of the articular-
cartilage layer, there exists an undisputed need for an effective
cell-based repair strategy. We have to face the bleak fact that very
little progress in this area has been made since the bone-marrow-
stimulation techniquee of whichmicrofracturing/microdrilling is a
variant e was introduced by Pridie in the 1950s44. However, one
source of comfort is that cell-based cartilage-repair strategies, such
as the ACI-technique, do not elicit worse healing results than those
that are based on a stimulation of the bonemarrow. A reﬁnement of
the ACI-technique has been recently introduced, which involves a
selection from the harvested cells of speciﬁc sub-populations of
(characterized) chondrocytes with particularly high chondrogenic
potentials. However, 2 years after treatment according to the
reﬁned ACI-technique, the clinical beneﬁts were reported to be only
incremental126. And 5 years after treatment by microfracturing or
according to the reﬁned ACI-treatment, the clinical outcome was
ultimately the same in each patient-group127, despite some differ-
ences during the follow-up course128.
Given the high degree of technological ﬁnesse that is now
achievable, and against the backdrop of knowledge and experience
that have been gained over the past 60 years with Pridie drilling
and over the last 20 to 30 years with the ACI-approach [as well as
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accessible to improvement. As aforementioned, in an attempt to
improve the clinical outcome of microdrilling and its reproduc-
ibility, the approach has been combined with the introduction of a
thin-layered, blood-absorbing matrix (enhanced microfracturing)
of either collagen types I and III64,65, “manipulated” collagen (as in
AMIC67) or chitosan glycerol phosphate41,66. The available data
afford evidence that the clinical results are reproducible68,71, and,
possibly, that the long-term outcome (compared to the conven-
tional technique) may be improved70. As heretofore mentioned, the
introduction of a local population of autologous stem cells (e.g., in
the form of small tissue-fragments, which could be derived from a
local source, such as the synovium) would probably be a fruitful
route to pursue in the future. However, the currently practiced
approaches, which involve the transplantation of either fragments
of juvenile allogeneic cartilage129e131 or pieces of adult autologous
articular cartilage129,132e134, are based on the false premiss that the
cells can migrate out of the tissue. Tissue-embedded chondrocytes
are incapable of migration; they can undergo only indirect trans-
location via a directional resorption of the surrounding matrical
coat and its neoformation135. Migration is possible only if the cells
undergo dedifferentiation (which occurs during the late stages of
osteoarthritis) and if the pericellular and territorial matrical com-
partments are destroyed by excessive catabolic activity136e138.
Clinical studies that have dealt with these approaches129,133 suffer
from fundamental shortcomings, which include insufﬁcient
numbers of patients, the absence of a basis for comparison (e.g.,
sham surgery), and the failure to instigate random-selection pro-
cedures. The data that have been gleaned from such trials serve
only to demonstrate that the interventions can be safely imple-
mented; they do not permit the drawing of comparative conclu-
sions. The same arguments hold true for clinical studies that have
evaluated the efﬁcacy of approaches involving the application of a
bone-marrow-aspiration concentrate (BMAC)139e141 or of platelet-
rich-plasma (PRP), either alone or in combination with
BMAC140,141. PRP- and BMAC-based strategies are classical examples
of empirical, “alchemistic” approaches to the engineering of carti-
laginous tissue. Using the former approach (PRP), an ill-deﬁned
broth of multifarious growth factors at unknown concentrations
and with diversee antagonistic as well as synergisticeworkings is
administered; and using the latter (BMAC), a similarly ill-deﬁned
soup of diverse cells in variable numbers is applied. Owing to
inter-individual variations in the compositions of these pot-pourris,
the exerted effects will be likewise variable and thus irreproduc-
ible; and even if these are positively rated, an identiﬁcation of the
key-player(s) is impossible.
Current research activities relating to tissue-engineering-
based strategies
Many more research teams around the world are now moving
away from an overly empirical approach to cartilage repair, which
was hitherto the norm, towards a more biologically rational one.
Current activities tend to focus on the elaboration of novel tissue-
engineering-based strategies142. Tissue engineering can be deﬁned
as the art of reconstitutingmammalian tissues, both structurallyand
functionally. Such reconstructive processes can be conducted (1)
entirely in vitro, (2) initially in vitro and then in vivo (in situ), or (3)
entirely in vivo.
Three key constituents usually form the building blocks of a
tissue-engineering-based approach: a matrix scaffold, cells, and
signalling molecules (such as growth factors or genes). Most of the
experience so far gained with these techniques has been derived
from in-vitro studies, although experiments with laboratory ani-
mals and humans have also been conducted. In the followingsections, the key constituents of a tissue-engineering-based
approach to cartilage repair are described.
Cell sources
Success in tissue-engineering-based strategieswouldobviate the
need for the transplantation of cartilaginous tissue. And if appro-
priate precursor-cell pools could be identiﬁed, then the numerous
problems that are associated with the use of donor (allogeneic)
material would be circumvented. Precursor-cell pools of diverse
tissue origin are known to existwithin adultmammalian organisms,
each of which has the potential to differentiate into cartilage-
producing chondrocytes and which can be used for trans-
plantation purposes. And in some instances, the tissue of origin has
the potential for self-repair after the removal of not insubstantial
quantities of material. The tissue sources include the cambial layers
of theperichondriumand theperiosteum, thebone-marrowstroma,
the synovial membrane, muscle, fat143e145 and adult cartilage itself
(autologous or allogeneic chondrocytes146e148). Perinatal cells149, as
well as foetal or embryonic stemcells and chondroblasts, can also be
employed150. The search for suitable and hitherto untested types
continues unabated151e153. Due to the limited availability of autol-
ogous chondrocytes, the focus is now more on allogeneic sources.
However, the use of allogeneic cells raises other problematic issues,
such as bioincompatibility and immunogenicity142,152.
Mesenchymal stem cells (MSCs) are now frequently used
experimentally for cartilage-tissue engineering, owing to their ca-
pacity for self-renewal and their accessibility143e145. Amongst the
various tissue sources, bone-marrow-derived MSCs have been the
most intensively investigated, both in vitro and in vivo, since the
time of their original isolation by Friedenstein in 1966154. Bone-
marrow-derived MSCs evince a high capacity for chondrogenesis
only in the presence of appropriate stimulation factors78,155,156. In a
clinical setting, Kuroda et al.157 treated a large full-thickness artic-
ular-cartilage defect within the femoral condyle of an athlete with
autologous bone-marrow-derived stromal cells. The bone marrow
was aspirated from the patient's iliac crest 4 weeks before surgery
and the cells were expanded in culture after their separation from
the erythrocytes. The undifferentiated cells were then embedded
within a collagenous gel, which was transferred to the articular-
cartilage defect and covered with an autologous periosteal ﬂap.
Although the knee-outcome scores improved with time, biopsies
revealed the presence of ﬁbro-, not of hyaline, cartilage. In this
study, no exogenous agents were applied to guide the course of
differentiation. This fact suggests that the formation of a hyaline
type of repair cartilage by MSCs requires the presence of appro-
priate stimulation factors (see Signalling molecules), which may be
locally absent, or present at insufﬁciently high levels to guide the
process of differentiation in the desired direction. Although MSCs
have been claimed by some investigators to furnish their own
supply of growth factors158,159 and to be conferred with the ca-
pacity for immunomodulation160, experimental experience gained
over the past 20 years in the ﬁeld of cartilage repair has revealed
these activities e if indeed they exist e to be too low to support an
efﬁcacious healing response.
One of the limitations of bone-marrow-derived MSCs is that
their chondrogenic potential declines with increasing patient
age125. MSCs that are derived from the synovium do not suffer from
this drawback161. Furthermore, the chondrogenic potential of MSCs
originating from the synovium appears to be superior to that of
MSCs originating from either the bone marrow, the periosteum,
adipose tissue or muscle, at least in vitro77. However, as yet, we are
still in the dark as to which tissue source of MSCs is ideal for the
clinical repair of articular cartilage, since convincing in-vivo data
have not been forthcoming to date.
Table I
Chemical classes of matrix
1. Protein-based polymers
Fibrin
Collagen
Gelatine
2. Carbohydrate-based polymers
Polylactic acid
Polyglycolic acid
Hyaluronan
Agarose
Alginate
Chitosan
3. Artiﬁcial polymers
Dacron (polyethylene terephthalate)
Teﬂon (polytetraﬂuoroethylene)
Carbon ﬁbres
Polyesterurethane
Polybutyric acid
Polyethylmethacrylate
Hydroxyapatite
4. Within/between classes
Cross-linkage
Chemical modulations
Geometrical modiﬁcations (to produce ﬁbrillar forms or foams)
Matrix combinations
Reproduced e in a slightly modiﬁed form e with permission from30.
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dous hurdles must still be surmounted before the goal of cartilage
regeneration can be achieved. Our knowledge of the regulatory and
signalling pathways that are implicated in the biology of stem cells
generally, and more especially that govern their commitment to
differentiate along a speciﬁc course and to form a speciﬁc type of
cartilaginous tissue, namely, ﬁbro-, hyaline or elastic, is still very
incomplete. Information appertaining to the temporal course of
chondrogenic differentiation and its regulation is also lacking. With
respect to induced pluripotent stem (iPS) cells162, for example, it
still remains to be ascertained whether the point in time at which
they are induced to undergo committed differentiation along a
speciﬁc course is or is not programmed into their genetic appa-
ratus; and, if so, whether the “age”, viz., maturation state, of the
newly-formed cells and tissuesmatches that of the donor. The same
questions arise also when dealing with foetal, embryonic or adult
stem cells. Moreover, we are still in the dark as to whether the
tissue-differentiation and growth processes that ontogenetically
span decades in time can indeed be speeded up therapeutically so
as to be completed within the matter of a few weeks only.
Furthermore, although our knowledge of the human genetic code is
now fairly complete, information relating, for example, to theTable II
Matrix requirements
Matrix property Biologi
1. Porosity Cell m
2. Carrier Lodgem
3. Adhesion Cell att
4. Biodegradability Physio
5. Volume stability Smoot
6. Biocompatibility Good c
7. Bonding Enhanc
compa
8. Internal cohesiveness Preven
9. Elasticity Resilie
10. Structural anisotropy Promo
Matrix properties speciﬁc to the mode of surgical application
A. Fluid state during application with subsequent solidiﬁcation in situ Arthro
B. Stiff and amenable to press-ﬁtting Arthro
Reproduced e in a slightly modiﬁed form e with permission from30.programming of joint-surface shape or of locational differences in
structure, composition and thickness23,24, is lacking. Knowledge of
this kind is indispensable for the fruitful development of more
sophisticated epigenetic and higher-level approaches to cartilage
repair. Only against a background of improved knowledge and
understanding can we hope to engineer a mechanically-competent
and durable type of articular cartilage. At present, research in this
area has attained a hyatal status and is moving in circles rather than
forward.
Matrix scaffolds
The use of matrices as cell-carriers in cartilage-repair strategies
dates back to the 1960s163. Many different types of matrix have
been testede not only in vitro but also in experimental animals and
human patients e for their capacity to facilitate or promote
articular-cartilage repair. Thesematrices can be broadly categorized
according to their chemical nature into protein-based polymers,
carbohydrate-based ones, artiﬁcial materials, and combinations of
these (Table I). Even when a naked matrix (viz., one that carries no
cells or signalling substances) is deposited within an articular-
cartilage defect, it must be considered as an information-carrying
device: its three-dimensional structure will, according to its
peculiar geometrical conﬁguration, speciﬁcally guide, or at least
inﬂuence, the process of tissue growth, whilst the chemical and
physical properties of its surface will impact cell attachment and
the binding of growth factors in the niche environment. Hence, as
an “active biologic”, such a naked matrix will elicit a biological
response within a bodily tissue-compartment, which may or may
not be desirable, but which cannot be prevented unless speciﬁc
modulations of an appropriate nature are made to guide the pro-
cess in the desired direction [e.g., by means of AMIC (see discussion
above)]. The basic requirements of a matrix to be used in a
biological environment are summarized in Table II (see also
Refs. 27,117,118).
Although some of the listed materials are already in clinical
use164, most of them, and especially the synthetic ones, are still
being tested in preclinical trials165. Moreover, using scaffolding
materials that have been applied for awhile in the ﬁeld of cartilage
repair, such as collagen166, ﬁbrin167, hyaluronan168,169 and poly-
lactate170, as well as those that have appeared on the scene more
recently, attempts are now being made either to produce them in
nanoﬁbrillar forms171, to enhance their porosity172, or to manu-
facture them in a state that is conducive to injection173. The com-
mon aim of these endeavours is usually to create an absorbable,
biomimetic material174, even when using synthetic polymers, such
as polydioxanone175.cal basis
igration
ent and release of signalling substances
achment
logical remodelling
h surface contour of repair tissue ﬂush with that of native articular cartilage
ontact with the native-tissue compartment
es interfacial integration between collagenous ﬁbrils in repair- and native-tissue
rtments
tion of matrix outﬂow
ncy during and following dynamic or static deformation
tion of native anisotropic tissue organization
scopic implantation
tomy (open surgery of a joint)
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folds176,177. These bilayers consist of two different materials: an
upper one that is deemed to be conducive to chondrogenesis and
which is destined for the cartilaginous compartment of osteochon-
dral defects, and a lower one of a ceramic-like substance, which can
bepress-ﬁttedasaplug into the subchondral bone176. Apart fromthe
obvious issues that must be addressedwhen testing a scaffold, such
as biocompatibility, biodegradability and toxicity, its integration
withnative cartilage is also a troublesomeproblem, andone that has
not yet been overcome178. During the past decade, nomatrices with
basically new chemical features have been inaugurated. However,
physical or chemical modiﬁcations to existing materials have been
effected, with a view to enhancing the efﬁcacy of clinically-
established methodologies, such as microfracturing/micro-
drilling41,64e66, byAMIC68,70, or ACI (byMACI)116, or, in the context of
more experimental tissue-engineering-based approaches, with the
aim of guiding cartilage-formation in a spatially-deﬁned manner
[three-dimensional bioprinting (see discussion below)]. The dearth
of genuine innovation in thisﬁeld partially reﬂects the unfavourable
investment climate that prevails in the commercial world, which
encourages low-cost, incremental improvements in existing stra-
tegies rather than revolutionary novelty. This is a regrettable
circumstance, since it is precisely this ﬂux of ingenuity that is now
needed to push research in a really fruitful direction. However, one
positive aspect of this dilemmatic situation is that any newly-
conceived therapeutic principle must now be not only of a truly
impressive nature but also backed up by rigorous experimentation
before any willingness to invest in clinical trials can be expected.
Signalling molecules
One of the trends now foremost in the ﬁeld of tissue engineering
relates to the elaboration of constructs that consist not only of a
matrix and cells but also of signalling molecules to speciﬁcally
guide the course of differentiation in the desired direction. In most
cartilage-engineering strategies, the chosen cell type is applied
together with free or appropriately-encapsulated growth factors.
The efﬁcacy of various growth factors to induce chondrogenesis has
been evaluated mainly in vitro and to only a limited degree in vivo
(for reviews, see Refs. 179e183). In-vitro experiments have involved
various combinations of matrix, cell type and growth factors. These
include collagenous matrices containing bone-marrow-derived
stromal cells and transforming growth factor (TGF)-ß1184,185,
agarose matrices containing chondrocytes and ﬁbroblast growth
factor (FGF)-2186, ﬁbrinous matrices containing chondrocytes and
insulin-like growth factor (IGF)-1187, and polylactatous matrices
containing perichondrial cells and TGF-ß1188. In some instances,
MSCs have been cultured in the absence of a matrix (viz., under
scaffold-free conditions), namely, as high-density pellets (or ag-
gregates)183,189,190. Under such conditions, not only growth factors,
but also dexamethasone, a synthetic glucocorticoid, is frequently
applied. However, this agent can elicit undesired effects in a
manner that depends upon the source of the cultured cells and the
absence or presence of the natural (physiological) extracellular
matrix78,155,156. Successful testing in vivo has been achieved using
equine191 and mature miniature-pig models72. The study that was
conducted using the latter model has served to show how different
the in-vivo situation may be from the in-vitro one. Under in-vitro
conditions, various types of growth factor have been shown to
support chondrogenic activities192, whereas in vivo, principally only
those of the TGF-b superfamily are effective193. A recently-
discovered compound, namely, kartogenin194, is now attracting
some attention. However, this molecule appears to exert a gener-
alized anabolic effect on chondrocytes rather than being specif-
ically chondrogenic.There are three possible approaches to the engineering of
articular cartilage. According to the ﬁrst, the repair tissue is engi-
neered completely in vitro, the fully-differentiated construct being
then implanted within the defect void. The advantage of this
approach lies in the fact that cell metabolism and differentiation
are subject to better control in vitro than in vivo, provided that the
appropriate bioreactor systems195,196, growth factors and delivery
systems are available. Its drawbacks are, that the problems asso-
ciated with the integration and the mechanical ﬁxation of the
repair tissue cannot be readily anticipated and solved. Moreover,
the simulated mechanical-loading conditions of the extracellular
matrix may not be ideally suited to the speciﬁc needs of the pro-
spective repair site. In addition, biocompatibility and immunolog-
ical problems are frequently associated even with this in-vitro
approach and in the absence of a scaffold197. Furthermore, the
natural curvature of the joint surface poses a challenge to the
process of press-ﬁtment whereby the engineered construct is
introduced into the defect void.
The second approach, which is more frequently adopted, aims to
engineer only the basic building block, namely, a matrix scaffold
containing a homogeneous population of cells, and signalling mol-
ecules that are entrapped within an appropriate delivery system.
The vehicle-bound signalling molecules ensure that the desired
differentiation process takes place in a controlled and timely
manner in vivo and that chondrocytic activity within the repair
tissue is sustained. According to this approach, the differentiation
and the remodelling of the repair tissue occur in vivo under physi-
ological conditions of mechanical loading. Repair tissue that is
formed in situ is more likely to adhere to and integrate with native
articular cartilage than is that produced in vitro, and itwill also adapt
naturally to the contour of the synovial joint, provided that appro-
priate measures are taken to promote the bonding of the implant
that has been generated in culture198e200. One of the disadvantages
of this “second” approach is that cell activity is more difﬁcult to
control on a long-term basis. Moreover, appropriate measures must
be taken to avoid “contamination” from cells and signalling sub-
stances that are involved in the spontaneous healing response, since
the tissue thereby formed would compromise the quality and the
mechanical competence of the ﬁnal repair-composite.
The third approach involves the direct application of exogenous
growth factors (entrapped within a matrix) to the defect site; these
then stimulate the intrinsic formation of cartilaginous tissue in
situ72. An appropriate matrix is ﬁrst introduced into the defect to
deﬁne the space that is to be repaired. The laying of this physical
“track” is necessary to guide the movements of the intrinsic pre-
cursor cells, which have a limited spatial awareness21. The growth
factors are usually introduced into thematrix in twodifferent states:
as a freely-soluble agent e to stimulate the immediate recruitment
of the intrinsic population of precursor cells from their site of origin,
theirmigration into the defect area, and their proliferation therein21
e and in a vehicle-bound form for gradual delivery at a steady rate
that is sustained for several weeks e to stimulate the chondrogenic
differentiation of the defect-ﬁlling population of cells72. Hence, an
intelligent, internally-programmed matrix is applied to the defect.
The freely-soluble signalling agent that is applied is usually IGF-1,
bFGF or a TGF-b (at low concentration). As aforementioned, the
growth factor in this form stimulates the recruitment of precursor
cells from the synovium21, theirmigration into the defect space, and
their subsequent proliferation therein. The vehicle-bound signalling
agent that is applied to induce the chondrogenic differentiation of
the defect-ﬁlling population of cells is usually amember of the TGF-
b superfamily, for example, bone morphogenetic protein (BMP)-2,
BMP-9, BMP-13 or TGFb1 (at high concentration). Various drug-
delivery systems have been employed, including microspheres, li-
posomes, microparticles and ﬁbrillar networks. The principle
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1991201. A full description of the strategy appeared in the literature
in 199621 and then, in an optimized form, in 200172. The approach
has since been summarized in several publications27,202. The prin-
ciple has been recently conﬁrmed by an independent group of in-
vestigators203 (2010) using TGF-b3 as the chemotactic and
chondrogenic differentiation agent, a hydrogel as the drug-release
system, and three-dimensional-printed poly-ε-caprolactone-hy-
droxyapatite as the matrix. Unfortunately, the authors chose not to
cite the original pioneering work on this topic and coveted the idea
as a newone. Actually, the novelty of the study lay in the use of poly-
ε-caprolactone-hydroxyapatite as a three-dimensionally-printed
matrix. A matrix of this kind is implemented with a view to guiding
tissue formation in a spatially-deﬁned manner. As appertaining to
articular cartilage, the aim is to reproduce the anisotropic organi-
zation of the chondrocytes and their extracellular matrix that is so
characteristic of the mature tissue and that is indispensable for its
mechanical competence. Although three-dimensional bioprinting is
an old technique (for a review of the topic, see Ref. 204), it has
recentlyundergone a revival: owing to technological advancements,
sophisticated materials can nowadays be manufactured with
greater facility and more cheaply than heretofore.
The material of which the matrix is formed needs to be sufﬁ-
ciently porous to allow the inﬁltration of cells27,201 and also biode-
gradable. Ideally, it should also have a well-deﬁned anisotropic
organization, which forces the cells to align themselves into vertical
columns during the process of remodelling205 and which is
important for the mechanical competence of the tissue as a whole,
as aforementioned. In this context, the three-dimensionally-printed
matrix that represented the sole novelty of the study by Lee et al.203
may be advantagenous.
One problem appertaining to the chondrogenic differentiation
of the defect-ﬁlling population of cells that we have recently
addressed relates to the timely arrestation of the process prior to
the stage of terminal hypertrophy andmatrix mineralization73. This
undesired event can be avoided by the addition of TGF-b1 at a low
concentration73. Other investigators have achieved similar results
using alternative agents206e212.
Consequently, to achieve optimal cartilage-repair results, mini-
mally three sets of growth-factor-stimulated “activities” need to be
embraced in the applied cocktail of signalling agents72e74. This ne-
cessity, which is not always recognized (cf203), renders the approach
unattractive to cost-conscious commercial parties and/or investors.
Principally two novel growth-factor-based therapeutic strate-
gies are now at the conceptual stage of development: the afore-
mentioned one, which is designed to recruit cells with
chondrogenic potential from a local intrinsic source, such as the
synovial membrane21,72,203; and a second approach, which involves
the injection into the defect site of MSCs that have been transfected
with genes encoding the factors necessary for chondroprogenitor
commitment213,214. Both approaches are still at a preliminary stage
of development; exhaustive short- and long-term preclinical
studies79 are requisite prior to the launching of clinical trials.
Scientiﬁc evaluation
After perusing this review article, the reader will no doubt be
left with the impression that in the area of cartilage repair, research
activity over the past 10 years or so has turned around in circles, not
moved forward in excitingly new and fruitful directions e which is
a regrettable situation for hopeful patients. The circumstance is the
less excusable in so far as the technological advancements that have
been made during this time span have greatly aided the probing of
many facets of cartilage biology, thereby permitting an enrichment
of knowledge and understanding in the targeted disciplines.In this review, suggestions for fruitful directions of pursuit in the
future have been made. But what is now needed is a revolutionary
turnaround in our conception of cartilage repair and a more thor-
ough and systematic approach to its evaluation. We should not
stagnate, but break free of the bounds of our comfort zone as
represented by the old well-worn ruts e the trusted, tried and
tested tracks of yore e the pursuit of which can contribute no more
than incremental or cosmetic information to the body of existing
data that has accumulated over the past decade.
A fundamental change in the general attitude of scientists, PhD-
students and supervisors towards the evaluation of cartilage repair
is also called for. In many laboratories, the analytical process is
conducted on an elementary e almost routine e and insufﬁciently
discriminative level. Nowadays, repair cartilage is all too commonly
presented as a tissue that contains lacuna-mantled cells (chon-
drocytes), that stains histochemically with a cationic dye (such as
Toluidine Blue or Safranin O), and that manifests immunohisto-
chemical reactivity for type-II collagen. Attempts to quantify the
characteristics of the tissue are conﬁned to parameters that insuf-
ﬁciently describe the true nature of articular cartilage. These pa-
rameters are gauged using subjective and biased scoring systems,
such as those propounded by Mankin215, O'Driscoll216 and the
ICRS217. The parameters that are evaluated using these tools afford
no information relating to the maturation status of the repair
cartilage, viz., whether it is of a foetal, ontogenetically-transient,
early postnatal or adult type; nor is any information gleaned as to
whether the repair cartilage is of a joint-speciﬁc type or not.
Similarly, these rudimentary evaluations yield no information
respecting the metabolic status of the tissue, viz., whether the
anabolic and the catabolic activities are in a state of equilibrium or
not. Very often, the repair cartilage is sweepingly designated as
being “hyaline-like” without adequate supportive evidence. The
repair cartilage needs to be subjected to a rigorous analysis: its
maturation status should be deﬁned; so, too, should its architec-
tonic and ultrastructural features, including the degree of anisot-
ropy. These and other structural characteristics should be
quantiﬁed morphometrically, not using subjective scoring systems.
Another drawback of scoring-system-based approaches is that
they attempt to assess too many parameters, whereas ideally, three
to maximally four pertinent ones should be evaluated. The impact
of a repair strategy on the individual parameters can vary greatly
(ranging from positive to negative), and yet, in the end, an average
score for all is calculated. Hence, there is the danger that positive
ﬁndings for some parameters will be “diluted” by negative effects
on others, and, in extreme cases, that falsely-negative results will
be generated; the reverse situation also holds true. Unfortunately,
one cannot escape from the reality that scoring-system-based ap-
proaches are subjective and biased, since they attempt to describe
the situation that appertains within the volume of a defect void
from two-dimensional images of histological sections without
respecting the laws of random sampling and stereology. And it is
precisely these laws that a morphometric analysis does respect. The
authors feel the necessity of dissuading investigators from imple-
menting a scoring-system-based approach, which may not “go
downwell”with thosewho have used such regimes for many years.
However, “a man should never be ashamed to own he has been
wrong, which is but saying, in other words, that he is wiser today
than he was yesterday” (Alexander Pope: Miscellanies). In-
vestigators should not be daunted by the prospect of undertaking a
morphometric analysis. Once the basic principles of the approach
have been grasped (for a simple introduction to these, see Ref. 218),
all that is needed for an objective and unbiased evaluation of a few
pertinent parameters are correctly-sampled tissue-sections and an
appropriate grid-system. The investigator's task is then a simple
“counting” one; moreover, he or she is not burdened with the
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system is implemented.
In addition to structural data, information appertaining to the
post-translational metabolic status of the chondrocytes should be
derived by monitoring the gene-expression levels of representative
anabolic and catabolic markers.
The conception of truly novel therapeutic approaches to carti-
lage repair is greatly encouraged. But all the ingenuity in the world
will be as wind-blown chaff unless we make a stand against the
quick-and-easy attitude that is now sadly enough the brand of
modern times.
Prospects for the future
Current trends in the induction of cartilage repair seem to point
towards a more tissue-engineering-based approach. The aim of
tissue engineering is to develop methodologies whereby bodily
defects can be repaired in such a manner as to restore the structure
and the functional competence of the affected tissues. Tissues and
organs that do not heal spontaneously are induced to repair by
attempting to overcome the biological limitations that undermine
this process in Nature. At the stage of its conception, a tissue-
engineering-based principle must be screened to ascertain the
size of the patient population that will be targeted, its socioeco-
nomic impact, the feasibility and likely cost of its manufacture, and
its surgical practicability. Hence, tissue engineering is an interdis-
ciplinary enterprise79.
There exists no magical formula for the engineering of a product
that would be universally applicable to all bodily tissues. An engi-
neered construct must be tailor-made on a tissue-speciﬁc basis. To
yield a product that will be beneﬁcial to the targeted patient pop-
ulation, a tissue-engineering-based principle should be experi-
mentally developed along systematic and, whenever possible,
rational lines, and in the light of a thorough understanding of the
biological system in hand.
Conclusion
We are still a long way from achieving our goal of cartilage
regeneration. However, Nature affords the clues to this end if they
are sought, and if we have the fortitude to pursue them rationally
and systematically. Only by following such a course canwe hope for
ultimate success in the generation of an endurable, structurally and
functionally competent type of cartilaginous repair tissue.
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